CERENO SCIENTIFIC AB B (4A1) - Total Liabilities
Based on the latest financial reports, CERENO SCIENTIFIC AB B (4A1) has total liabilities worth €150.20 Million EUR (≈ $175.60 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 4A1 cash flow metrics to assess how effectively this company generates cash.
CERENO SCIENTIFIC AB B - Total Liabilities Trend (2021–2025)
This chart illustrates how CERENO SCIENTIFIC AB B's total liabilities have evolved over time, based on quarterly financial data. See shareholders equity of CERENO SCIENTIFIC AB B for net asset value and shareholders' equity analysis.
CERENO SCIENTIFIC AB B Competitors by Total Liabilities
The table below lists competitors of CERENO SCIENTIFIC AB B ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
HomesToLife Ltd
NASDAQ:HTLM
|
USA | $86.58 Million |
|
Polight ASA
OL:PLT
|
Norway | Nkr33.56 Million |
|
Wam Research Ltd
AU:WAX
|
Australia | AU$17.07 Million |
|
Mountain & I Acquisition Co Corp
NASDAQ:MCAA
|
USA | $16.41 Million |
|
1Stdibs.Com Inc
NASDAQ:DIBS
|
USA | $37.89 Million |
|
CI Games SA
WAR:CIG
|
Poland | zł121.22 Million |
|
Midnight Sun Mining Corp
V:MMA
|
Canada | CA$678.98K |
|
Tectonic Metals Inc
V:TECT
|
Canada | CA$3.57 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down CERENO SCIENTIFIC AB B's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 4A1 company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.59 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CERENO SCIENTIFIC AB B's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CERENO SCIENTIFIC AB B (2021–2025)
The table below shows the annual total liabilities of CERENO SCIENTIFIC AB B from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €150.20 Million ≈ $175.60 Million |
-32.29% |
| 2024-12-31 | €221.85 Million ≈ $259.36 Million |
+223.57% |
| 2023-12-31 | €68.56 Million ≈ $80.16 Million |
+384.80% |
| 2022-12-31 | €14.14 Million ≈ $16.53 Million |
+32.50% |
| 2021-12-31 | €10.67 Million ≈ $12.48 Million |
-- |
About CERENO SCIENTIFIC AB B
Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden and internationally. The company's lead drug candidate is CS1, a product candidate that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an … Read more